According to Zhitong Finance App, Yipinhong (300723.SZ) announced that a phase II/III clinical trial of AR882 (generic name: deuteropentinolate) capsules for treating patients with gout with hyperuricemia, led by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently obtained top-line analysis data. Preliminary statistical results showed that AR882 showed positive efficacy and good safety in participants with gout with hyperuricemia. The test results were ideal and achieved the intended goals.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.